Clinical Research Directory

Inclusion Criteria: Adults with known or suspected coronary artery disease based one of the following criteria: 1. Abnormal CMR without stress in a previous CMR measurement (e.g. new onset of wall motion abnormalities or reduced LVEF) 2. Referral from local cardiologist based on one of the following criteria: 1. Patients has a diagnosed coronary artery disease based on other methods 2. Patients has a high-risk profile based on risk stratification using clinical evaluation (ESC-Score \> 5%), the assessment of LV function by resting echocardiography, and, in the majority of cases, non-invasive assessment of ischaemia or coronary anatomy. 3. Patients demonstrate chronic kidney disease (CKD III or higher) and diabetes 4. Patients demonstrate history of peripheral artery disease (PTA/Stent) or TEA of the carotids or previous operation of atherosclerotic aortic aneurysms * Male or female subjects aged ≥18 years * Patient fully responsible and can understand/sign the study from a legal aspect Exclusion Criteria: * Patient refusal to participate * Any contraindication to perform an MRI exam * Known Hypersensitivity to the active substance or to any of the excipients in Regadenoson or GE-267 * Any contraindication to aminophylline or theophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms * Unstable angina that has not been stabilized with medical therapy * Severe hypotension * Decompensated states of heart failure * Severe Arrhythmias * Contraindication to the cardiac MRI examination (e.g. inability to hold breath; severe claustrophobia, metallic devices such as pace makers) * Second or third degree atrioventricular (AV) block or sinus node dysfunction, unless these patients have a functioning artificial pacemaker * Known pregnancy or lactation